세계의 심장 부정맥 치료 시장 2019-2023

■ 영문 제목 : Global Cardiac Arrhythmias Therapeutics Market 2019-2023

Technavio가 발행한 조사보고서이며, 코드는 IRTNTR31782 입니다.■ 상품코드 : IRTNTR31782
■ 조사/발행회사 : Technavio
■ 발행일 : 2019년 7월 29일
■ 페이지수 : 130
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일
■ 조사대상 지역 : 글로벌
■ 산업 분야 : 산업미분류
■ 판매가격 / 옵션 (부가세별도)
Single User (1명 열람용)USD2,500 ⇒환산₩2,800,000견적의뢰/주문/질문
Five User (5명 열람용)USD3,000 ⇒환산₩3,360,000견적의뢰/주문/질문
Enterprise License (전사내 공유가능)USD4,000 ⇒환산₩4,480,000견적의뢰/구입/질문
가격옵션 설명
- 지불하실 금액은 상기 원화금액에 부가세(10%)를 더한 금액입니다.
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제이며, 세금계산서 발행 가능합니다.
본 조사보고서는 심장 부정맥 치료의 세계시장에 대해서 조사분석한 자료로서, 심장 부정맥 치료의 세계시장규모, 시장동향, 시장환경 분석, 세그멘트별 분석, 지역별 분석 (미주, 유럽, 아시아), 관련기업 정보등이 포함되어 있습니다.
■ 보고서 개요

Global Cardiac Arrhythmias Therapeutics Market: About this market
Cardiac arrhythmias therapeutics are pharmaceutical agents that are used to normalize the issue of cardiac arrhythmia. Technavio’s cardiac arrhythmias therapeutics market analysis considers sales from both oral and intravenous applications. Our analysis also considers the sales of cardiac arrhythmias therapeutics in North America, Europe, Asia and the rest of the world (ROW). In 2018, the oral segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as Low cost, easy to consume, no pain, extended-release effect of oral arrhythmias therapeutics will play a significant role in the oral segment to maintain its market position. Also, our global cardiac arrhythmias therapeutics market report also looks at factors such as the growing prevalence of thrombosis, availability of precise diagnostic methods, rising awareness about cardiovascular diseases. However, black box warning associated with cardiac arrhythmias therapeutics, availability of substitute products, stringent regulatory environment may hamper the growth of the cardiac arrhythmias therapeutics industry over the forecast period.

Global Cardiac Arrhythmias Therapeutics Market: Overview

Availability of precise diagnostic methods

The availability of precise diagnostic methods, like electrocardiogram (ECG) Hotter monitors, event monitors, stress IQ tests, echocardiogram, cardiac catheterization, electrophysiology study (EPS), and head-up tiff table tests have led to increase in the diagnosis rate of cardiac arrhythmias, thus contributing to increased prescription of therapeutics for cardiac arrhythmias. Such factors will lead to the expansion of the global cardiac arrhythmias therapeutics market at a CAGR of over 4% during the forecast period.

The advent of gene therapy to control ventricular rate in AF

The current treatment therapy for AF involves the use of antiarrhythmic drugs to sustain the sinus rhythm or drugs that can curb the conduction in the atrioventricular (AV) node in order to control the ventricular rate. The medication therapy used for the treatment of arrhythmia exerts its pharmacological effect by targeting the conduction properties of the AV node- by suppressing the calcium current or by altering the cholinergic and adrenergic tone. Therefore, the global cardiac arrhythmias therapeutics market presents an urgent need for the development of biological drugs, which can target the gene and thus, improve cardiac functioning. Ongoing research in this area is expected to have a positive impact on market growth during the forecast period.

For the detailed list of factors that will drive the global cardiac arrhythmias therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global cardiac arrhythmias therapeutics market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cardiac arrhythmias therapeutics manufacturers, that include Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., and Sanofi.

Also, the cardiac arrhythmias therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

■ 보고서 목차

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

Market segmentation by application

Comparison by application

Oral – Market size and forecast 2018-2023

Intravenous – Market size and forecast 2018-2023

Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

The advent of gene therapy to control ventricular rate in AF

Technological advances enabling the early detection of cardiac arrhythmias

Growing R&D efforts by vendors

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Bayer AG

Eli Lilly and Co.

GlaxoSmithKline Plc

Pfizer Inc.

Sanofi

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Application – Market share 2018-2023 (%)

Exhibit 19: Comparison by application

Exhibit 20: Oral – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Oral – Year-over-year growth 2019-2023 (%)

Exhibit 22: Intravenous – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Intravenous – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by application

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Top 3 countries in North America

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in Europe

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 36: Top 3 countries in Asia

Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 39: Top 3 countries in ROW

Exhibit 40: Key leading countries

Exhibit 41: Market opportunity

Exhibit 42: Diagnostic methods

Exhibit 43: Side-effects of cardiac arrhythmias therapeutics

Exhibit 44: Substitute products to cardiac arrhythmias therapeutics

Exhibit 45: Impact of drivers and challenges

Exhibit 46: Vendor landscape

Exhibit 47: Landscape disruption

Exhibit 48: Vendors covered

Exhibit 49: Vendor classification

Exhibit 50: Market positioning of vendors

Exhibit 51: Bayer AG – Vendor overview

Exhibit 52: Bayer AG – Business segments

Exhibit 53: Bayer AG – Organizational developments

Exhibit 54: Bayer AG – Geographic focus

Exhibit 55: Bayer AG – Segment focus

Exhibit 56: Bayer AG – Key offerings

Exhibit 57: Bayer AG – Key customers

Exhibit 58: Eli Lilly and Co. – Vendor overview

Exhibit 59: Eli Lilly and Co. – Business segments

Exhibit 60: Eli Lilly and Co. – Organizational developments

Exhibit 61: Eli Lilly and Co. – Geographic focus

Exhibit 62: Eli Lilly and Co. – Segment focus

Exhibit 63: Eli Lilly and Co. – Key offerings

Exhibit 64: Eli Lilly and Co. – Key customers

Exhibit 65: GlaxoSmithKline Plc – Vendor overview

Exhibit 66: GlaxoSmithKline Plc – Business segments

Exhibit 67: GlaxoSmithKline Plc – Organizational developments

Exhibit 68: GlaxoSmithKline Plc – Geographic focus

Exhibit 69: GlaxoSmithKline Plc – Segment focus

Exhibit 70: GlaxoSmithKline Plc – Key offerings

Exhibit 71: GlaxoSmithKline Plc – Key customers

Exhibit 72: Pfizer Inc. – Vendor overview

Exhibit 73: Pfizer Inc. – Business segments

Exhibit 74: Pfizer Inc. – Organizational developments

Exhibit 75: Pfizer Inc. – Geographic focus

Exhibit 76: Pfizer Inc. – Segment focus

Exhibit 77: Pfizer Inc. – Key offerings

Exhibit 78: Pfizer Inc. – Key customers

Exhibit 79: Sanofi – Vendor overview

Exhibit 80: Sanofi – Business segments

Exhibit 81: Sanofi – Organizational developments

Exhibit 82: Sanofi – Geographic focus

Exhibit 83: Sanofi – Segment focus

Exhibit 84: Sanofi – Key offerings

Exhibit 85: Sanofi – Key customers

Exhibit 86: Validation techniques employed for market sizing

Exhibit 87: Definition of market positioning of vendors



■ 기재된 기업 리스트

Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., and Sanofi.


■ 조사 방법

1차조사 (업계 전문가, 기업, 대리점, 고객에 대한 심층 인터뷰를 포함), 2차조사 (Technavio 플랫폼, 산업자료, 기업 보고서, 뉴스 기사, 애널리스트 레포트, 무역협회, 정부발행 자료 등)

※본 조사보고서 [세계의 심장 부정맥 치료 시장 2019-2023] (코드 : IRTNTR31782) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [세계의 심장 부정맥 치료 시장 2019-2023] 에 대해서 E메일 문의는 여기를 클릭하세요.